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Abstract
Murine models of intestinal cancer are powerful tools to recapitulate human intestinal cancer, understand its
biology and test therapies. With recent developments identifying the importance of the tumour microenvironment
and the potential for immunotherapy, autochthonous genetically engineered mouse models (GEMMs) will remain
an important part of preclinical studies for the foreseeable future. This review will provide an overview of the
current mouse models of intestinal cancer, from the ApcMin/+ mouse, which has been used for over 25 years,
to the latest ‘state-of-the-art’ organoid models. We discuss here how these models have been used to define
fundamental processes involved in tumour initiation and the attempts to generate metastatic models, which is the
ultimate cause of cancer mortality. Together these models will provide key insights to understand this complex
disease and hopefully will lead to the discovery of new therapeutic strategies.
© 2015 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
Keywords: colorectal cancer; crc; invasion; metastasis; transplantation; GEMM; adenomatous polyposis coli; organoids
Received 3 September 2015; Revised 21 September 2015; Accepted 23 September 2015
No conflicts of interest were declared.
Introduction
In the Western world, colorectal cancer (CRC) is the
second-highest cause of cancer mortality [1]. In ∼90%
of fatal cases, metastasis is the cause of mortality. In
the early 1990s Fearon and Vogelstein [2] postulated
that mutations in CRC occur in a sequential manner,
with specific mutations being associated with tumour
initiation, eg the adenomatous polyposis coli (APC)
gene, and other mutations occurring later that drive
progression, eg TP53. Recent DNA sequencing studies
confirmed the common co-existence of these mutations
within individual CRC tumours. A recent theory of
CRC, referred to as the ‘Big Bang’ model, describes
tumour growth as an expansion populated by various
heterogeneous subclones. Initial mutations in genes,
such as APC and KRAS (‘public mutations’), are carried
by all subclones, and subsequent ‘private’ mutations are
acquired later in individual subclones [3].
In 80–90% of CRCs the initial step is proposed to be
the loss of the tumour-suppressor gene APC, and this is
often called the ‘classical’ route [4]. Inactivation of APC
induces stabilization of β-catenin (as it can no longer be
targeted for degradation) and translocation of β-catenin
to the nucleus. In the nucleus β-catenin acts as a tran-
scriptional co-activator, interacting with TCF4/LEF1
transcription factors to up-regulate expression of WNT
target genes [4,5]. Another early event during tumour
progression is the mutation of the proto-oncogene
KRAS. KRAS is mutated in 40–50% of human CRCs,
with> 75% of these mutations located in codon 12,
which lock KRAS in the active GTP-bound state [6].
Further common mutations occur to activate the PI3
kinase signalling pathway, eg in PTEN or PIK3CA.
This pathway is associated with driving cell growth,
metabolism and tumour progression. TGFβ pathway
abrogation in CRC can occur through mutation of
either TGFβ-receptor 1 (TGFBR1) or TGFBR2. Fur-
thermore, TGFβ pathway inactivation can occur via loss
of heterozygosity (LOH) of chromosome 18q, where
SMAD2 and SMAD4, two downstream mediators of
TGFβ signalling, are located. Another gene deleted
in colorectal cancer (DCC) is also localized to 18q
and encodes a netrin receptor that controls differen-
tiation and tumourigenesis [7,8]. A further late-stage
event, mainly associated with tumour cell invasion,
is the mutation of the tumour-suppressor gene TP53
[6]. Interestingly, tumours carrying TP53 and APC
mutations are often associated with increased rates of
chromosomal instability (CIN) [9–11].
Sequencing studies have also revealed that many other
mutations occur in individual CRC tumours, although
at much lower frequencies (the ‘private’ mutations
described above). The importance of these is still unclear
and many represent passenger mutations which might
have no function [12–14]. Mouse models still provide
the ‘gold standard’ test to see whether these mutations
can functionally affect the development of cancer.
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Table 1. Intestinal GEMMs of invasion and metastasis
Model Invasion Metastasis Reference
Apc1638N/+ Increased mucosal and submucosal
invasion
Liver metastasis (1) Fodde [42]
AhCre Apcfl/+ KrasG12V 17% invasive carcinoma, into smooth
muscle
Sansom [44]
AhCre Apcfl/+ Ptenfl/fl 32% early invasive adenocarcinomas;
22% advanced adenocarcinomas
Marsh [77]
Fabp1Cre PIK3ca* Invasive adenocarcinoma (analysed at
day 40)
Leystra [78]
Fabp1Cre PIK3ca* ApcMin/+ Invasive adenocarcinoma Deming [79]
VillinCre Apc1638N/+ TgfbrIIfl/fl 41% invasive carcinoma Munoz [81]
ApcΔ716/+ Smad4+/− 54% submucosal invasion Takaku [82]
ApcMin/+ Smad3−/− Invasion to submucosa and into the
muscularis propria
Sodir [83]
Apc580D/+ Smad2+/− 10–15% stroma invasion Hamamoto [84]
ApcMin/+ p53−/− Muscularis mucosae Halberg [87]
AhCre Apcfl/+ p53fl/fl 25% stromal invasion Muller [88]
AhCre Apcfl/+ p53R172H/+ 100% stromal invasion Muller [88]
ApcMin/+ ΔcyEphB2 100% (>30 tumours from seven
different mice) classified as
intramucosal adenocarcinomas
Batlle [90]
ApcMin/+ EphB3−/− 47% of the tumours were scored as
invasive carcinoma
Batlle [90]
VillinCre Braf LSL–V637E/+ 14% (4/29) of mice of mice showed
invasive carcinoma at age 10
months
Metastasis to the mesenteric lymph
nodes in 20% (1/5) of the mice
Rad [113]
VillinCre Braf V637E/+ p53R172H/+ 56% (10/18) of mice showed invasive
carcinoma at age 10 months
Metastasis to the lung, pancreas, liver
and mesenteric lymph nodes in
25% (3/12) of the mice
Rad [113]
VillinCre Braf V637E/+ p16−/− 59% (20/34) of mice of mice showed
invasive carcinoma at age 10
months
Metastasis to the lung, stomach, liver
and local lymph nodes in 25%
(3/12) of the mice
Rad [113]
VillinCreERT2 Apcfl/+ Ptenfl/fl KrasG12V/+ High-grade invasive carcinoma in 7%
of the tumours
Davies [114]
VillinCreERT2 Ptenfl/fl KrasG12V/+ 44% (12/27) showed invasion into the
intestinal wall
41% (n= 11/27) present metastases;
liver (7/11), pancreas (3/11), lymph
nodes (2/11) and lungs (1/11)
Davies [114]
VillinCre KrasG12V/+ TgfbrIIfl/fl 70% showed marked desmoplasia and
invasion
Lymph node and lung metastasis
in15% (3/20)
Trobridge [115]
VillinCre KrasG12V/+ Ink4a/Arf−/− Serrated invasive carcinoma in 76%
(13/17)
Metastasis to the lung in 62% (8/13)
of mice with invasive carcinoma
Bennecke [116]
VillinCreERT2 Nicd1LSL/+ p53fl/fl 59% showed invasion into muscularis
and adipocyte tissue
23% (n= 7/30) lymph node and 10%
(n= 3/30) liver metastases
Chanrion [121]
Of the remaining 20% of CRC tumours that do not
carry APC mutations, many of these are associated with
mutation of DNA mismatch repair (MMR) genes or
inactivation predominantly of the mismatch repair genes
MLH1 and MSH2 (Lynch syndrome) [15–17]. These
cancers have very high levels ofmutation rate, evidenced
by high levels of microsatellite instability, and are pre-
dominantly right-sided and carry an improved progno-
sis. Recently an excellent model of Lynch syndrome
has been developed through targeted deletion of Msh2
in the intestinal epithelium [18]. The mutational spectra
induced by a MMR defect leads to a distinct set of fur-
ther mutations within these cancers. Currently it is hard
to decipher the functional significance of these muta-
tions, as they may simply be marking the DNA repair
defect; however, other common mutations are found in
TGFBR2, ACTIVIN, BAX and MBD4. Exciting recent
data suggest that these cancers may be sensitized to
immune checkpoint inhibition, potentially as a result of
the higher levels of mutation [19].
Given all this information on the common mutations
that occur in CRC, mouse models can be developed that
are based on the genetic make-up of tumours, generating
realistic mouse models of the human disease. The suc-
cesses and challenges that still need to be overcome will
be the focus of this review. Due to space constraints, we
have limited our review to genetic models of cancer and
so do not discuss colitis-associated cancermodels within
the mouse (reviewed in [20,21]). A brief overview of the
models discussed in this review is provided in Table 1.
Mutation of APC leads to adenomas in mice
APC loss is the cause of familial adenomatous poly-
posis (FAP), a human autosomal dominant syndrome,
in which patients develop numerous colorectal polyps
[22,23]. Given the high prevalence of APC mutation in
sporadic colorectal cancer and APC being the causal
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Figure 1. Timeline of the development of murine intestinal cancer models. The ApcMin/+ mouse was developed in 1990 and recapitulates the
disease observed in FAP patients. In 1997, the first conditional deletion of Apc was performed in the colon and led to colonic adenomas.
Acute deletion of Apc throughout the intestine led to a crypt progenitor phenotype in which whole crypts were transformed. To model
more advanced disease, the Apc580S (and ApcMin/+) model was combined with commonly mutated oncogenes/tumour suppressor-related
genes (2000 onwards). This led to faster tumourigenesis and to increased penetrance of invasive adenocarcinomas but not metastasis. With
more interest in serrated models of CRC, models driven by Kras or Braf mutations were generated. These models lacked Apc mutation and
tumour latency was much increased. However, these models commonly generated adenocarcinoma that had the capacity to metastasize.
Most recently, tumour-derived and primary organoids transformed with common CRC mutations have been implanted into syngeneic or
immunocompromised mice, either subcutaneously or into the kidney capsule (2015). Metastasis has been observed from tumour-derived
organoids
gene for FAP, most of the models developed to mimic
colon cancer have centred on models carrying APC
mutation.
The most commonly used model is the multi-
ple intestinal neoplasia (MIN) model (referred to as
ApcMin/+; Figure 1) [24,25]. This autosomal dominant
mutation was generated by N-ethyl-N-nitrosourea
(ENU) mutagenesis. The mutagen caused a loss of
function mutation in the mouse Apc gene at codon 850.
During adulthood, spontaneous LOH of the other Apc
allele occurs and mice develop multiple intestinal ade-
nomas and a smaller number of colonic polyps [24,25].
A major difference between the ApcMin/+ mouse model
and the human disease is that human FAP patients
predominantly develop colonic lesions, whereas the
mice develop more polyps in the small intestine. Fur-
thermore, human FAP, if not treated, can progress to
invasive carcinoma; this is only very rarely reported
in mice, probably due to the high tumour burden in
these mice and the inability to intervene surgically. The
ApcMin/+ model has been utilized for a broad range of
studies; foremost have been chemoprevention studies
and functional testing of genes that might modify
intestinal tumourigenesis. Treatment studies of estab-
lished tumours have also occurred, although it should be
noted that if sporadic polyps appeared in patients, these
would be removed surgically with no further treatment.
Chemoprevention experiments have shown marked
effects with non-steroidal anti-inflammatory drugs
(NSAIDs), such as aspirin and celecoxib [cyclooxy-
genase (COX) inhibitor], although the mechanism
of prevention by aspirin is likely pleiotropic and the
suppression of tumourigenesis by celecoxib suggests
that inhibition of COX2 is important for chemopre-
vention [26,27]. This work has directly translated to
humans, where celecoxib reduces tumourigenesis of
FAP patients and aspirin strongly reduces the risk of
CRC development [28–30].
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Functional genetic studies have identified numer-
ous genes that modulate tumour development by both
acceleration and deceleration. Initial studies identified
modifier of MIN (MOM) loci through genetic linkage
studies in mice. MOM1 is located distal to chromo-
some 4. Interestingly, the orthologous region on the
human chromosome shows frequent LOH in CRC
[31]. The two genes located within the mouse MOM1
region are Plag2g2a and perlecan (Hspg2) and studies
have identified that disruption of Plag2g2a can slow
tumourigenesis [32]. Further modifiers of MIN have
been described and reviewed [33,34]. The identification
of MOM1 also highlighted the importance of mouse
genetic background on tumourigenesis [31,35].
ApcMin/+ C57BL/6 J mice develop 30 polyps on
average. Crossing these mice with AKR, MA or CAST
strains dramatically reduces the number of polyps,
indicating that the MOM1 locus is lost in C57BL/6 J
mice [35,36]. This has been tested by introducing distal
chromosome 4 from AKR mice into C57BL/6 J mice
[35]; congenic mice showed the semi-dominant function
of theMOM1 locus. Therefore, it is important to analyse
ApcMin/+ mice in a C57BL/6 J background. Otherwise,
tumour burden and latency varies strongly, potentially
masking the effects of the genes being tested. Many
other factors can modify intestinal tumourigenesis in
the ApcMin/+ mouse, such as diet and the microbiome
[37,38]. Recently, novel approaches have been used
to discover new modifiers of tumourigenesis in the
ApcMin/+ mouse; sleeping beauty transposon-mediated
mutagenesis identified hundreds of alleles that can
accelerate tumourigenesis in this system [14]. One
caveat that should be mentioned here is that if the
mutation causes late-stage progression, this might not
have a phenotype in a model that only predisposes to
adenoma.
Given the high penetrance of the APC mutation in
human CRC, many other Apc-truncating alleles have
been generated. These include an allele, Apc1322T/+,
which very closely mimics the mutations that occur
in human cancer (APC codon 1309) [39] and an Apc
knockout allele that produces no protein [40]. All
the alleles that cause a loss of the ability of APC to
bind β-catenin lead to intestinal tumour predisposition;
however, precise kinetics and tumour features can
alter depending on the allele. For example, Apc1322T/+
shows increased levels of Lgr5 and stem cell markers
within tumours, although with a slight reduction in
general Wnt target gene expression, eg Axin2 [41].
Another interesting example of these mutations is
Apc1638N/+, which harbours a neomycin cassette in
antisense orientation within exon 15, resulting in a pro-
tein truncated at codon 1638, which is unstable. These
mice show few tumours (<10) and a long latency, and
develop adenocarcinoma along with infiltration into the
mucosa and submucosa [42]. Thus, mice might develop
tumours that more closely resemble human CRC if
there were a longer latency to tumour development that
allowed them to acquire further mutations that drive
progression.
Spatio-temporal control of gene expression
in vivo
The advent of Cre–Lox (Cre) technologies in the 1990s
enabled researchers to delete any gene in any tissue
of interest [43]. In this method, mice carrying a Cre
transgene (under the control of an inducible tissue spe-
cific promoter) are crossed to mice bearing an inducible
allele where the region that is to be deleted is flanked by
LoxP recombination sites. This can be either an essen-
tial exon(s) of a gene, to produce a conditional knock-
out, or a Stop motif to activate an oncogene, eg Kras
or Pik3, within adult tissue [44,45]. The inducibility of
Cre recombinases wasmost commonly achieved by cou-
pling the Cre enzyme to the oestrogen receptor, leading
to activation of Cre after administration of tamoxifen
[46]. Titration of Cre induction either via reducing the
inducing agent (taxmoxifen/viral) or Cre recombinase
also facilitates low levels of recombination, which was
hoped to overcome problems of multiple tumours per
mouse [47].
APC deletion
Acute deletion of both copies of Apc has revealed much
about the mechanism of early tumourigenesis. Shibata
et al [48] delivered Adenovirus–Cre to the colon and
showed that deletion of both copies (LoxP sites flank-
ing exon 14; Apc580S/580S; Apcfl/fl) was sufficient to drive
colon adenomas. Using a highly penetrant inducible
Cre (AhCre, which is driven by the Cyp1a1 promoter
and is inducible by β-naphthoflavone and VillinCreERT)
within the small intestine (and to a lesser extent the
colon), we [49] and Andreu et al [50] showed that Apc
loss had a dramatic impact on intestinal homeostasis.
Deletion of both copies of Apc results in a crypt pro-
genitor phenotype, which is characterized by increased
proliferation and altered migration and differentiation.
Notably, this phenotype was mediated by the Wnt tar-
get gene Myc [51,52]. We and others have identified a
number of Wnt-Myc targets important for this [53–55].
More recently, colon-specific deletion of Apc has been
achieved using a Cdx2P–CreERT2 transgenic mouse
and produced a very similar phenotype to that of dele-
tion of Apc in the small intestine [56]. Using constitu-
tive or inducible colon-specific Cre also overcomes the
problem of small intestinal tumour burden andmany dif-
ferent colon Cres (FABPCre, A33Cre, CDX2Cre) have
all been used to delete a single copy of Apc and generate
colonic adenomas [57–59].
The discovery of LGR5+ intestinal stem cells (ISCs)
in the small and large intestine not only led to funda-
mental changes in concepts on ISCs and homeostasis
but also allowed us to explore the impact of deleting
Apc in the ISCs [60]. LGR5 is a G-protein coupled
receptor that binds R-spondin and thereby enhancesWnt
signalling [61]. LGR5 was shown to be a ‘bona fide’
ISC marker using lineage tracing. In brief, a knock-in
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Lgr5CreER mouse was generated and interbred with the
Rosa26LSL–LacZ reporter mouse. Following Cre induc-
tion, LGR5 ISCs were able to stably generate all epithe-
lial lineages [60]. Notably, using Lgr5–CreER to delete
Apcwithin ISCs led to rapid formation of intestinal ade-
nomas, strongly suggesting that LGR5+ ISCs might be
the cells of origin for intestinal cancer [62]. Follow-
ing this study, many other stem cell markers have been
identified and, using a similar Cre knock-in approach,
ISCs have been shown to act as cells of origin for can-
cer whenApc is deleted or a constitutive-active β-catenin
is expressed [63–65]. Together these studies showed in
the mouse that ISCs are highly efficient cells of origin
for cancer.
However, two studies have recently demonstrated
that activation of Wnt signalling in differentiated cells
results in dedifferentiation and adenoma formation
[66,67]. This dedifferentiation seems to require further
events, eg inflammation or another oncogenic event, in
addition to deregulation of Wnt signalling. Activation of
β-cateninΔex3/+ and the inflammatory nuclear factor-κB
(NFκB) signalling pathway, in non-ISCs (using the
Xbp1–CreER), led to dedifferentiation and tumour
development [66]. The same study demonstrated that
concomitant Apc deletion with aberrant KrasG12D/+
expression results again in a NF-κB-dependent dedif-
ferentiation. This observation is in accordance with the
‘top-down’ model of CRC development, which is based
on the observation that early dysplastic human CRC
lesions predominantly locate to the luminal part and
not to the base of the crypt [68]. Another study inves-
tigating the potential transformation of differentiated
cells targeted Apc deletion to terminal differentiated
tuft cells, using a tuft cell marker, DCKL1. Although
Dckl1–Cre-mediated loss of Apc alone did not lead to
tumour formation, when Apc loss was combined with
dextran sodium sulphate (DSS) treatment (to induce
colitis) the mice developed tumours [67]. Therefore,
these studies show that mouse models can inform us
about the capacity of cells to act as cells of origin for
cancer. The key question that remains is whether they
do so in human cancer. Further cross-comparison with
human tumours and mathematical modelling is required
for us to progress beyond these ‘proof-of-principle’
experiments.
A fundamental drawback of Cre-mediated gene inac-
tivation is that this results in the permanent deletion
of a gene, and thus it is hard to assess the sustained
requirement for the initiating oncogene/tumour suppres-
sor gene. To address the continued reliance on Apc
loss and downstream Wnt signalling, two recent stud-
ies using doxycycline-inducible systems have shown
that, if APC expression is restored (through inducible
shRNA) or an inducible active β-catenin allele is turned
off, there is complete reversion to a normal intestinal
epithelium. This underlines the continued dependence
on Wnt signalling [31,69]. In all situations, withdrawal
of doxycycline led to down-regulation of Wnt sig-
nalling and complete tumour ablation via differentiation.
This even occurred in invasive adenocarcinomas also
carrying mutations in Tp53 and KrasG12D/+ [70]. There-
fore, GEMMs of CRC provided excellent ‘proof of
concept’ that a target remains important throughout all
stages of carcinogenesis.
Generating mouse models of adenocarcinoma
carrying Apc mutation
Generating mouse models of metastatic CRC has proved
to be difficult. One of the key steps towards modelling
metastasis is generating murine models of invasive ade-
nocarcinoma. Cellular invasion is a complex process in
which tumour cells escape from the adhesive epithe-
lium and cross the basement membrane, invading the
smooth muscle of the intestine. This is often associ-
ated with a change in cellular shape, gain of motil-
ity and loss of E-cadherin [71]. Single-cell migration
can be achieved by epithelial cells which undergo an
epithelial–mesenchymal transition (EMT), resembling
a developmental process [72]. This process is regu-
lated by intercellular communication of tumour cells
with their microenvironment, typically mediated by
cell–cell communication via chemokines or the extra-
cellular matrix (ECM) [73]. Notably, EMT has been
suggested to be a dominant process during human CRC
progression [74].
As mentioned above, CRC progression follows a dis-
tinct order of serial mutations [2]. Since Apc mutations
alone do not produce invasive tumours, later mutations
in the adenoma–carcinoma sequence have been added
to make mouse models of CRC more patient-relevant.
With a mutation rate of ∼40% in human CRC, KRAS
is one of the most frequently altered genes following
APC and is also described as an early event during
progression [2]. Mouse models combining mutation of
Apc with aberrant expression of mutated KrasG12V/+
resulted in a higher number of intestinal tumours with
an increased invasion of tumour cells to the surround-
ing stroma [44,75]. Given the high frequency of PTEN
and PI3KCA mutations in human CRC [76], both Pten
and Pik3ca mutant mice have been intercrossed with
mice carrying Apcmutation. These additional mutations
rapidly accelerate tumourigenesis and increase tumour
progression so that the mice develop adenocarcinomas
[77]. When active Pik3ca is expressed alone within the
intestine, the mice develop invasive mucinous adenocar-
cinoma with no intermediate benign tumour stage [78].
Expression of KrasG12D/+ or KrasG12V/+ alone does not
show a similar phenotype; here the mice develop both
adenoma and adenocarcinoma, but at very long latencies
(>500 days) [44]. Thus, in mouse models, Apc muta-
tion acts as an initiator, reducing latency and increasing
tumour burden. This in itself is a problem, as the mice
develop multiple tumours and thus may need to be euth-
anized due to burden before any tumours have had the
opportunity to metastasize [79].
To overcome the issue of excessive tumour bur-
den in mouse models, low-level recombination with
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Cre-expressing viruses targeting the colon has been per-
formed [48,80]. Using AdCre, Hung and colleagues
developed a metastatic model of CRC, based around
loss of Apc and KrasG12D/+ mutation. One caveat of this
model is the need for surgery, which may explain the
surprising lack of uptake by the research community of
what appears to be an excellent model.
Loss of TGFβ signalling is a common step during
CRC progression. In the mouse, Apcmutation in combi-
nation with inactivation of various components of TGFβ
signalling (Tgfbr2, Smad2, Smad3 or Smad4) gener-
ally leads to the production of invasive adenocarcinoma,
although again not metastasis [81–84]. Smad3 loss in
theApcMin/+ model also altered tumour location, as more
tumours arose in the distal colon [83]. One of the postu-
lated mechanisms for how loss of TGFβ drives invasion
(although it is required for processes such as EMT) is
that mutations in the tumour lead to a protumourigenic
tumour microenvironment. For example, the increased
invasion observed in cis-ApcΔ716/+Smad4+/− mice was
suggested to be mediated by recruitment of immature
myeloid cells (iMCs) from the bone marrow, leading to
secretion of matrix metalloproteinases (MMPs) at the
invasion front of intestinal tumours [85].
The tumour-suppressor gene TP53 is altered in
50–60% of human CRCs. Surprisingly, deletion of
Tp53 in an outbred mouse background did not result
in increased tumour progression in the ApcMin/+ model
[86]. However, when analysed in a pure C57BL6/J back-
ground, ApcMin/+ Tp53−/− compound mice revealed a
tendency to higher tumour burden and the devel-
opment of invasive tumours [87]. In human CRC,
gain-of-function mutations of TP53 are common, par-
ticularly TP53R175H. Expression of a single copy of
the mouse version of this mutant, Tp53R172H/+, with
deletion of a single Apc allele, led to invasive tumour
progression in all mice [88].
Collectively, it is clear that, when tested in mice,
nearly all the common human mutations lead to
increased tumour progression and development of ade-
nocarcinoma, although alone these additional mutations
do not provoke rapid tumourigenesis. One interesting
hypothesis is that Apc mutation might make it harder
for tumours to become metastatic in mice. This con-
cept arose from work on two different targets of the
Wnt pathway, Ephb2/3 and Tiam1. EphrinB receptors
(EphB) are direct Wnt target genes that control the
architecture of the normal intestinal epithelium [89].
Interestingly, EPHB2, EPHB3 and EPHB4 are induced
during early stages but down-regulated during CRC
progression. Ephb3−/− in the ApcMin/+ mice leads to
conversion of 47% of tumours to adenocarcinoma,
whilst ΔcyEphb2 deletion in the ApcMin/+ model reduces
the number of tumours formed, but those tumours
exhibit increased invasion [90]. Loss of Tiam1, a
pro-adhesive RAC–guanine nucleotide exchange fac-
tor (GEF), strongly suppresses tumourigenesis in the
ApcMin/+ mice but resultant tumours are eventually
invasive. Thus, it appears (at least in mice) that induc-
tion of the Wnt signalling programme favours benign
tumour formation and thus additional mutations are
required to drive further progression, which may in part
overcome some of the pro-adhesive consequences of
APC loss.
Modelling CRC metastasis with transplantation
Transplantation models are used to test pathways
involved in invasion and metastasis that might be thera-
peutically targetable. These xenograft (human cell line)
models result in desired characteristics, such as invasion
and metastasis [91]. However, these characteristics are
dependent on the route of inoculation. Subcutaneously
injected tumour cells rarely, if ever, produce any metas-
tases, but cells injected into the caecum, tail vein,
spleen, portal vein or kidney capsule can metastasize to
liver, lung and bones. Dependent on the site of injection,
eg tail vein, many of the barriers that cancer cells face,
which stop metastasis, such as extravasation or invasion
through the basement membrane, may be lacking and
it is important to remember these points. Experiments
are performed in immune-compromised mice (widely
used strains are nude or SCID mice) [92–97], and
therefore lack a number of important tumour cell–host
immune system interactions. Nevertheless, studies
using human CRC cell lines have demonstrated the
importance of the protumourigenic microenvironment.
Orthotopically injected TGFβ-over-expressing HT29
and KM12L4a CRC cells activated IL-11 secretion from
mouse cancer-associated fibroblasts, causing increased
metastasis [98]. To overcome the problem of using
immune-compromised mice, allografts of mouse CRC
cell lines can be used. These have been very important
for modelling immunotherapy strategies. For example,
the cell lines CT26 and MCA38, which were generated
from mouse colorectal tumours, have been injected
orthotopically to the caecum and rectal wall of Balb/c
and C57BL6/J mice, respectively, and have developed
liver metastasis [93].
With the discovery of LGR5+ stem cells in the intes-
tine, and following the isolation of these cells, Sato
et al [99] developed ex vivo organoid cultures. These
‘mini-guts’ can be grown in a three-dimensional (3D)
manner and they build tissue-like structures [99]. Out-
growth of wild-type spheres requires the presence of
Paneth cells, which provide LGR5+ cells with niche fac-
tors [100]. These cultures therefore represent an excel-
lent opportunity to model the mutations common in
colon cancer. To manipulate gene expression in these
organoids, a Cre recombinase-inducible retrovirus vec-
tor system has been developed [101]. Deletion of Apc in
these organoids results in transformation, which is char-
acterized by a morphological change to a more rounded
spheroid shape and R-spondin-independent growth due
to hyper-activated Wnt signalling [102]. Notably, these
cells can be isolated from Villin–CreERApcfl/fl crypts
only 2 days after tamoxifen application to the mice.
Additional mutation of KrasG12D/+ and Tp53R172H/+ or
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deletion of Ptenfl/fl confers the ability of these spheres to
grow in nude mice [66,103–105]. The multi-hit theory
proposed by Fearon and Vogelstein [2] was recapitu-
lated in mouse organoids by simultaneous deletion of
Apc, expression of KrasG12D/+ and deletion of Tp53 and
Smad4 (AKPS). These spheres have an invasive pheno-
type similar to that of human CRC [106].
Further validation of the sequential alteration of
major pathways in CRC has now also been proved
in organoids from normal human crypt stem cells, by
using CRISPR/CAS9 technology [107]. The resulting
AKPS cells show features of invasive carcinoma when
subcutaneously injected into immunocompromised
mice [9]. Another study described that Apc, Kras,
Smad4, Tp53, PIK3CAE545K (AKSTP) mutant cells
grow when engrafted under the kidney capsule of
Nod–scid/IL2Rγ-null mice. However, injection of these
cells into the spleen gives rise only to micrometastases
in the liver, whereas cells derived from humanmetastatic
CRC form macrometastases. This work suggested that,
in addition to the major driver mutations, further alter-
ations are required for metastatic progression and for
the outgrowth of CRC metastases in the liver [108].
Organoids may therefore help us decipher the con-
sequences of the major mutations in CRC and be
very useful in high-throughput screening for new ther-
apies and potential therapeutic stratification. Already,
much progress has occurred in the screening of tumour
organoids from humans [109], providing promise for
personalized/stratified therapy. It should be noted, how-
ever, that so far most of the screening has been done with
organoid cultures in Matrigel®, and it will be impor-
tant to see how microenvironmental changes and the
culture of spheres might alter the response of these
drugs; we have shown that basic properties, such as
the ratio of E-cadherin:β-catenin, are very different in
the in vivo setting versus cell culture [110]. These new
organoid models should lead to both the reduction and
replacement of animal experiments. Given the need
to test therapies in a 3D environment with an intact
tumour stroma, there is still a very important role for
autochthonous models, but hopefully experiments per-
formed in organoids will predict in vivo responses better
than other model systems.
GEMMs of metastatic intestinal cancer
One of the major goals of utilizing mouse models of
cancer is to recapitulate the human disease in order
to produce models to test treatments. Thus, to predict
response in this setting, we need models that metastasize
and these models are still lacking. Thus far, most of our
more successful models of metastasis are still of long
latency and low penetrance. Also, most of these models
do not carry mutation of APC. In this section we will
describe these models.
In addition to the classical model of CRC progres-
sion, alternative routes to CRC have been described
[6]. One alternative route is the serrated route, which is
characterized by hyperplastic lesions and a saw-toothed
(serrated) histology of the intestinal epithelium [111].
Molecular differences between the classical and serrated
route also exist. The serrated route is characterized by
initial BRAF or KRAS mutations and no APC mutations
[112]. In a mouse model of serrated CRC, the expres-
sion of oncogenic Braf LSL–V637E/+ from its endogenous
promoter led to the full progression of serrated hyper-
plasia to adenoma and finally to metastatic carcinoma.
However, latency was long and the percentage of metas-
tasis was low with Braf LSL–V637E/+ alone (one of five
mice). A possible increase in metastasis was detected
when mutant Tp53R172H/+ (three of 12 mice) or p16fl/fl
(three of 12 mice) were also mutated in addition to
Braf mutation, but latency and penetrance were still low
[113]. A further model of serrated tumourigenesis that
progresses to adenocarcinoma was driven by mutation
of KrasG12V/+ and Ptenfl/fl deletion; here, 41% of mice
developed metastasis, with over half developing in the
liver [114]. Another model that has shown metastasis
is KrasG12D/+ mice combined with deletion of Tgfbr2;
here, CRC cells spread to local lymph nodes and the
lung in 15% of themice. This dysplastic progressionwas
triggered by hyper-activated EGFR signalling [115].
Lung metastasis was detected in 62% of mice with con-
comitant KrasG12D/+ activation and Ink4a/Arf−/− dele-
tion; primary invasive tumours showed serrated mor-
phology and p16-dependent depression of senescence
[116]. It is interesting to note that all these models have
in common a long latency and a lack of Apc muta-
tion. However, in all models, high levels of Wnt sig-
nalling were observed in the adenocarcinoma andmetas-
tases that arose, suggesting that Wnt activation may
progress these lesions from serrated lesions into ‘bona
fide’ adenocarcinomas. The relevance of these serrated
models has recently come to the fore, given that CRCs
which have the poorest prognosis often have a ‘serrated’
signature [117].
Notch signalling is a key regulator of intestinal epithe-
lial cell fate during normal homeostasis and contributes
to tumour development [118]. Genetic alterations in
the Notch pathway leading to human CRC have not
been reported. However, FBXW7 is altered in 20% of
human CRCs and can control Notch receptor stability
[119]. The function of Notch signalling in intestinal
mouse models is controversial, as over-expression of
the intracellular active domain of the Notch-receptor 1
(Nicd1LSL–GFP) in combination with the ApcMin/+ muta-
tion generates higher numbers of adenomas which
were higher-differentiated compared to the control
[120]. However it has recently been shown that aberrant
expression of Nicd1 in combination with Tp53 deletion
in the mouse intestine generates adenocarcinomas that
exhibit markers of EMT. Analysis of thesemice revealed
that 23% had lymph node infiltration and 10% showed
spread of tumour cells to the liver [121]. Lymph node
infiltration with an EMT of the primary tumour has also
been reported when Tp53 was deleted in IEC and mice
where challenged with AOM [122]. It will be therefore
of interest to discover whether any of these models can
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produce metastasis with a higher penetrance and faster
latency when further oncogenic/tumour suppressor
mutations are added.
Other species
During recent years, other animal models of CRC have
been developed in both rats and pig. Both, especially
the pig, can recapitulate human physiology and phar-
macology in a much better way than mice. In rats, two
models of CRC were developed by administration of
ENU, the samemutagen used for generating theApcMin/+
mouse [123,124]. The most appropriate of these is the
ApcPirc/+ rat, which harbours a mutation in Apc which
converts lysine→Stop at codon 1137 [123]. These rats
exhibit strikingly similar pathology to human CRC, with
the development of tumours with intramuscular invasion
[125,126]. The porcine model of FAP was created by
generating porcine ES cells carrying an Apc1311 muta-
tion [127]. Germline heterozygous pigs were developed
that went on to develop multiple polyps by age of 1 year
(both low- and high-grade dysplasia) and so act as an
excellent model of FAP. Taken together, these new mod-
els open new avenues to model early-stage human CRC,
but still lack metastasis.
Conclusion and future work
It is 25 years since the publication of reports of the
ApcMin/+ mouse and this model has been extensively
used to characterize the mechanism, modifiers and
potential therapeutic strategies for early-stage intestinal
tumourigenesis [128]. Development of models that more
closely mimic late-stage disease for routine use by the
community have lagged well behind, so there is not a
routine GEMM for CRC that has a short latency and high
penetrance. The recent excitement over new subtypes
of CRC and potential stratification of patients by muta-
tion and/or subtype makes the need for model systems
more important than ever. Moreover, as immunother-
apy trials become more and more the norm in cancer
research, the need for immunocompetent autochthonous
models to test rational combinations is vital. The advent
of organoids over the past 10 years from both mouse and
human normal intestine and cancer offers excellent new
model systems. Transplantation of these are currently
non-orthotopic but in the future orthotopic injection may
provide new models of metastatic CRC. GEMMs will
remain vital to understand how the common co-existing
mutations cooperate in a natural environment. Current
challenges are to assess how stroma and microbiota
affect drug response, and these will need to be performed
in situ. While we have not succeeded so far in the devel-
opment of metastatic CRC models, many fundamental
discoveries have been made about stem cells, homeosta-
sis and transformation, so the community has failed very
successfully! Our future aims must be to better model,
understand and treat the later stages of CRC.
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